Stockholders’ Equity (Tables)
|
6 Months Ended |
Jun. 30, 2026 |
| Stockholders’ Equity [Abstract] |
|
| Schedule of Estimated Using the Black-Scholes Option-Pricing Model |
The fair value of the April 2026 Warrants, April Placement Agent Warrants and other warrants were estimated using the Black-Scholes option-pricing model with the following assumptions: | | | April 2, 2026 | | | June 4, 2025 | | | Exercise price | | | $0.85 to $0.875 | | | $ | 1.00 | | | Term (years) | | | 5.0 to 5.5 | | | | 2.0 | | | Expected stock price volatility | | | 120.35 | % | | | 129.68 | % | | Risk-free rate of interest | | | 3.94 | % | | | 3.87 | % |
|
| Schedule of Warrant Activity |
A summary of warrant activity for the six months ended June 30, 2026 is as follows: | | | Number of Warrants | | | Weighted Average Exercise Price | | | Total Intrinsic Value | | | Weighted Average Remaining Contractual Life (in years) | | | Outstanding as of December 31, 2025 | | | 1,740,752 | | | $ | 4.38 | | | $ | - | | | | 2.37 | | | Granted | | | 3,000,001 | | | | 0.85 | | | | - | | | | - | | | Expired | | | (56,932 | ) | | | 56.25 | | | | - | | | | - | | | Outstanding as of June 30, 2026 | | | 4,683,821 | | | | 1.49 | | | | - | | | | 4.06 | | | Warrants exercisable as of June 30, 2026 | | | 1,826,677 | | | $ | 2.49 | | | $ | - | | | | 2.18 | |
|
| Schedule of Black-Scholes Option-pricing Model Assumptions |
The fair value of option grants was estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions: | | | Six Months Ended June 30, | | | | | 2026 | | | 2025 | | | Exercise price | | $ | 0.7083 | | | $ | 1.55 | | | Term (years) | | | 5.0 | | | | 5.0 | | | Expected stock price volatility | | | 120.79 | % | | | 118.32 | % | | Risk-free rate of interest | | | 4.19 | % | | | 4.59 | % |
|
| Schedule of Option Activity |
A summary of option activity under the Company’s equity incentive plans for the six months ended June 30, 2026 is presented below: | | | Number of Shares | | | Weighted Average Exercise Price | | | Total Intrinsic Value | | | Weighted Average Remaining Contractual Life (in years) | | | Outstanding as of December 31, 2025 | | | 1,260,362 | | | $ | 4.340 | | | $ | 111,250 | | | | 8.2 | | | Employee options issued | | | 1,050,000 | | | | 0.71 | | | | - | | | | - | | | Expired | | | - | | | | - | | | | - | | | | - | | | Outstanding as of June 30, 2026 | | | 2,310,362 | | | $ | 2.69 | | | $ | 40,300 | | | | 8.7 | | | Options vested and exercisable as of June 30, 2026 | | | 2,310,362 | | | $ | 2.69 | | | $ | 40,300 | | | | 8.7 | |
|
| Schedule of Stock Options Outstanding |
A summary of stock options outstanding as of June 30, 2026 by price range is as follows: | | | Options outstanding and exercisable | | | Range of Exercise Prices | | Number of Shares | | | Weighted Average Remaining Contractual Life (in years) | | | Weighted Average Exercise Price | | | Up to $2.59 | | | 2,233,000 | | | | 8.8 | | | $ | 0.98 | | | $14.75 to $76.25 | | | 62,562 | | | | 5.2 | | | $ | 32.95 | | | Above $76.25 | | | 14,800 | | | | 3.5 | | | $ | 131.50 | | | Options outstanding and exercisable as of June 30, 2026 | | | 2,310,362 | | | | 8.7 | | | $ | 2.69 | |
|
| Schedule of Stock-Based Compensation Expense |
Stock-based compensation expense for the three and six months ended June 30, 2026 and 2025 was as follows: | | | Three Months Ended June 30, | | | Six Months Ended June 30, | | | | | 2026 | | | 2025 | | | 2026 | | | 2025 | | | Employee stock option awards | | $ | 625,485 | | | $ | — | | | $ | 625,485 | | | $ | 219,929 | | | Non-employee restricted stock awards | | | 51,594 | | | | — | | | | 51,594 | | | | — | | | Non-employee stock warrant awards | | | — | | | | 55,525 | | | | — | | | | 55,525 | | | | | $ | 677,079 | | | $ | 55,525 | | | $ | 677,079 | | | $ | 275,454 | |
|
| Schedule of Stock-Based Compensation Expense Included Within Research and Development and General and Administrative Expenses |
For the three and six months ended June 30, 2026 and 2025, the amount of stock-based compensation expense included within research and development and general and administrative expenses was as follows: | | | Three Months Ended June 30, | | | Six Months Ended June 30, | | | | | 2026 | | | 2025 | | | 2026 | | | 2025 | | | Research and development | | $ | - | | | $ | - | | | $ | - | | | $ | - | | | Professional fees | | | 51,594 | | | | 55,525 | | | | 51,594 | | | | 55,525 | | | General and administrative | | | 625,485 | | | | - | | | | 625,485 | | | | 219,929 | | | | | $ | 677,079 | | | $ | 55,525 | | | $ | 677,079 | | | $ | 275,454 | |
|